AtriCure's Q2 Earnings Exceed Expectations, Driven by Strong Franchise Growth and Clinical Trial Progress
AtriCure, a leading medical technology company, recently announced its Q2 2026 earnings results, exceeding expectations with worldwide revenue of $154 million and growth of 13%.
According to Michael Carrel, President and CEO, the U.S. business led the growth with an increase of 14% year-over-year, fueled by continued adoption of key products such as CryoSphere MAX in the pain management franchise, AtriClip FLEX-Mini and PRO-Mini devices in the appendage management franchise, and the Encompass clamp in the open ablation franchise.
The company's adjusted EBITDA reached $27 million, with net income coming in at $9 million. This reinforces AtriCure's progress toward improving profitability and demonstrating the overall strength of its business.
Carrel highlighted one of the company's key strategic initiatives, the BoxX-NoAF clinical study, which aims to demonstrate the benefits of ablation and LAA management in cardiac surgery procedures for patients without a history of AFib. The trial has surpassed the 50% enrollment mark with over 500 patients participating, putting it on track to complete full enrollment of 960 total patients by the end of this year.
Post-operative AFib places a significant burden on patients and healthcare spending exceeds $2 billion annually in the U.S. alone. The magnitude of this unmet need further underscores the critical importance of this trial, positioning AtriCure for clinical trial data readouts in the first half of 2027.
The company is also making great progress with its LeAAPS clinical trial, which investigates the stroke reduction benefit of left atrial appendage management in cardiac surgery patients without AFib. Over 6,500 patients are enrolled in this study, with outcomes expected to be a powerful catalyst for AtriCure's growth in the cardiac surgery market.
AtriCure's pain management franchise had another fantastic quarter, delivering 27% worldwide growth driven primarily by the adoption of CryoSphere MAX. The company continues to add accounts at a robust pace and remains at the front end of a long growth trajectory as it penetrates deeper into thoracic surgery and sees building traction in sternotomy procedures.
Recent evaluations of CryoSphere MAX at two major cancer centers in the U.S. have yielded positive outcomes, with AtriCure expanding its field team to support this growth. With these clinical trials and franchise performance driving progress, AtriCure is well-positioned for continued success in the second half of 2026.
